He Worked for a Law Firm Consulting on an Anti-Trans Supreme Court Case. Then We Asked About These Racist Posts
https://www.wired.com/story/lawfair-anti-trans-supreme-court-racist-posts/
Sep 10, 2024 - A WIRED investigation reveals that one of two lawyers known to have worked for or with Lawfair, a firm working on a case that could affect minors’ access to gender-affirming care, has ties to accounts with long histories of posting white supremacist content.
0
Goldman Sachs to post $400 million hit to third-quarter results as it unwinds consumer business
https://www.cnbc.com/2024/09/09/goldman-sachs-to-post-400-million-hit-in-third-quarter-over-consumer-business.html
Sep 09, 2024 - In late 2022, Goldman Sachs began to pivot away from its consumer operations, beginning a series of write-downs related to selling chunks of the business.
0
Post Holdings Drives Growth With Strategic Moves and Strong Brands
https://www.zacks.com/stock/news/2333524/post-holdings-drives-growth-with-strategic-moves-and-strong-brands?cid=CS-ZC-FT-analyst_blog|rank_focused-2333524
Sep 09, 2024 - POST is capitalizing on strategic acquisitions, effective pricing and a strong brand presence despite heightened competition in the staples sector.
0
Merck, Daiichi post mid-stage data for novel lung cancer drug
https://seekingalpha.com/news/4147833-merck-daiichi-post-trial-data-lung-cancer-drug?source=feed_sector_healthcare
Sep 07, 2024 - Merck (MRK) and Daiichi Sankyo (DSNKY) announce early results from a Phase 2 trial of lung cancer drug I-DXd, an antibody drug conjugate. Read more here.
0
Is Central Garden & Pet Stock Hold or Sell Post Q3 Earnings?
https://www.zacks.com/stock/news/2333048/is-central-garden-pet-stock-hold-or-sell-post-q3-earnings?cid=CS-ZC-FT-analyst_blog|rank_focused-2333048
Sep 06, 2024 - CENT is grappling with weak performance in its Pet and Garden segments, compounded by shifts in consumer demand.
0
Is Abercrombie's Post-Earnings Stock Dip a Green Light for Buyers?
https://www.zacks.com/stock/news/2333018/is-abercrombie-s-post-earnings-stock-dip-a-green-light-for-buyers?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2333018
Sep 06, 2024 - ANF stock struggles despite strong second-quarter fiscal 2024 results and strong fundamentals. We assess if this is an opportune time to buy the stock.
0
Vor Bio stock rallies post-market on trem-cel study data
https://seekingalpha.com/news/4147513-vor-bio-stock-rallies-post-market-on-trem-cel-study-data?source=feed_sector_healthcare
Sep 05, 2024 - Vor Bio (VOR) stock rallied 64% post-market after the company reported positive data for its gene-edited stem cell therapy trem-cel in the treatment of AML. Read more here.
0
Rubrik to Post Q2 Earnings: Should You Buy the Shares or Steer Clear?
https://www.zacks.com/stock/news/2332389/rubrik-to-post-q2-earnings-should-you-buy-the-shares-or-steer-clear?cid=CS-ZC-FT-analyst_blog|earnings_preview-2332389
Sep 05, 2024 - RBRK's fiscal second-quarter performance is likely to reflect benefits from its expanding clientele and increased demand for its data security solutions.
0
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
https://www.zacks.com/stock/news/2332368/biomarin-posts-27-biz-view-outlines-growth-plans-for-next-10-years?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2332368
Sep 05, 2024 - BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.
0
Old Dominion Posts Weak LTL Unit Performance for August
https://www.zacks.com/stock/news/2332151/old-dominion-posts-weak-ltl-unit-performance-for-august?cid=CS-ZC-FT-analyst_blog|company_news_corporate_actions-2332151
Sep 05, 2024 - ODFL's revenue per day fell 5.2% year over year in August 2024, owing to a 6.1% decrease in LTL tons per day.
0